VRTX — Patent US8415387 Expiration for SYMDEKO (COPACKAGED)
Nov 12, 2027, 12:00:00 AM UTC
Summary
The patent US8415387 for SYMDEKO (COPACKAGED), a product by Vertex Pharmaceuticals related to cystic fibrosis treatment, is set to expire on November 12, 2027. This patent covers compounds that modulate ATP-Binding Cassette (ABC) transporters and methods for treating diseases linked to these transporters. The expiration may have implications for market competition and future generics, impacting Vertex's competitive position in the cystic fibrosis therapeutics market.
Company
VERTEX PHARMACEUTICALS INC (VRTX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.vrtx.comSimilar Events
Patent US9670163 Expiration for SYMDEKO (COPACKAGED)
Vertex Pharmaceuticals Inc's patent US9670163 for its product SYMDEKO (COPACKAGED) is set to expire on December 28, 2026. The patent covers solid state forms of Compound 1, which is integral to the drug's formulation and effectiveness. The expiration of this patent could allow for the entry of generic alternatives, potentially impacting Vertex's revenue from SYMDEKO significantly.
Patent ExpirationPatent US7776905 Expiration for SYMDEKO
Vertex Pharmaceuticals Inc's patent US7776905 for the drug SYMDEKO, which is designed to modulate ATP-Binding Cassette (ABC) transporters, including the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), is set to expire on June 3, 2027. This event marks a critical point for investors, as the expiration may open the market to generic competition, potentially impacting Vertex's revenues from SYMDEKO significantly.
Patent EventPatent US8629162 Expiration for SYMDEKO
Vertex Pharmaceuticals Inc's patent US8629162 for SYMDEKO, a product that modulates ATP-Binding Cassette transporters for treating cystic fibrosis, is set to expire on June 24, 2025. This expiration may allow for increased competition as generic versions of the drug could enter the market, impacting Vertex's revenue from this product.
PatentPatent US9012496 Expiration for SYMDEKO
The expiration of Patent US9012496 for SYMDEKO, a drug developed by Vertex Pharmaceuticals Inc., is set for July 15, 2033. SYMDEKO is a pharmaceutical composition indicated for the treatment of CFTR-mediated diseases, such as Cystic Fibrosis. The patent encompasses the compound responsible for this formulation, which includes a specific chemical composition and various excipients for oral administration. The loss of patent protection may enable generic competition, potentially impacting Vertex's market share and profitability related to SYMDEKO.
Patent Expiration